Kronox Lab Sciences Ltd
Kronox Lab Sciences Limited manufactures and sells fine chemicals, inorganic chemicals, phosphates, and metallic chemicals in India and internationally. The company provides bulk reagents comprising ACS reagents, as well as LR, AR, and GR reagents; bulk ingredients that includes oral care, pharmacopoeia, food and nutraceutical, personal care and cosmetics, and veterinary pharma and animal health;… Read more
Kronox Lab Sciences Ltd (KRONOX) - Net Assets
Latest net assets as of September 2025: ₹1.01 Billion INR
Based on the latest financial reports, Kronox Lab Sciences Ltd (KRONOX) has net assets worth ₹1.01 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹1.13 Billion) and total liabilities (₹112.75 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹1.01 Billion |
| % of Total Assets | 89.99% |
| Annual Growth Rate | 30.7% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 15.67 |
Kronox Lab Sciences Ltd - Net Assets Trend (2022–2025)
This chart illustrates how Kronox Lab Sciences Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Kronox Lab Sciences Ltd (2022–2025)
The table below shows the annual net assets of Kronox Lab Sciences Ltd from 2022 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹901.05 Million | +35.89% |
| 2024-03-31 | ₹663.05 Million | +48.40% |
| 2023-03-31 | ₹446.79 Million | +10.72% |
| 2022-03-31 | ₹403.53 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kronox Lab Sciences Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 25.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹505.43 Million | 56.09% |
| Common Stock | ₹371.04 Million | 41.18% |
| Other Components | ₹24.58 Million | 2.73% |
| Total Equity | ₹901.05 Million | 100.00% |
Kronox Lab Sciences Ltd Competitors by Market Cap
The table below lists competitors of Kronox Lab Sciences Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Electromagnetica SA
RO:ELMA
|
$12.15 Million |
|
JG Environmental Technology Co.,Ltd.
TWO:6723
|
$12.16 Million |
|
Mercer Bancorp Inc.
OTCGREY:MSBB
|
$12.16 Million |
|
Samfine Creation Holdings Group Limited
NASDAQ:SFHG
|
$12.16 Million |
|
Medicus Pharma Ltd. Common Stock
OTCBB:MDCX
|
$12.15 Million |
|
CryoCell International Inc
NYSE MKT:CCEL
|
$12.15 Million |
|
The INX Digital Company Inc.
OTCQB:INXDF
|
$12.15 Million |
|
Galena Mining Ltd
AU:G1A
|
$12.14 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kronox Lab Sciences Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 663,050,000 to 901,049,000, a change of 237,999,000 (35.9%).
- Net income of 254,671,000 contributed positively to equity growth.
- Dividend payments of 18,535,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹254.67 Million | +28.26% |
| Dividends Paid | ₹18.54 Million | -2.06% |
| Other Changes | ₹1.86 Million | +0.21% |
| Total Change | ₹- | 35.89% |
Book Value vs Market Value Analysis
This analysis compares Kronox Lab Sciences Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.56x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 10.19x to 4.56x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-03-31 | ₹10.88 | ₹110.84 | x |
| 2023-03-31 | ₹12.04 | ₹110.84 | x |
| 2024-03-31 | ₹17.87 | ₹110.84 | x |
| 2025-03-31 | ₹24.28 | ₹110.84 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kronox Lab Sciences Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 28.26%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 25.42%
- • Asset Turnover: 1.01x
- • Equity Multiplier: 1.10x
- Recent ROE (28.26%) is below the historical average (32.86%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 33.77% | 16.57% | 1.45x | 1.41x | ₹95.92 Million |
| 2023 | 37.19% | 17.39% | 1.77x | 1.21x | ₹121.49 Million |
| 2024 | 32.20% | 23.76% | 1.21x | 1.12x | ₹147.21 Million |
| 2025 | 28.26% | 25.42% | 1.01x | 1.10x | ₹164.57 Million |
Industry Comparison
This section compares Kronox Lab Sciences Ltd's net assets metrics with peer companies in the Specialty Chemicals industry.
Industry Context
- Industry: Specialty Chemicals
- Average net assets among peers: $2,571,777,102
- Average return on equity (ROE) among peers: 15.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kronox Lab Sciences Ltd (KRONOX) | ₹1.01 Billion | 33.77% | 0.11x | $12.15 Million |
| Aarti Industries Limited (AARTIIND) | $8.75 Billion | 18.56% | 2.05x | $997.64 Million |
| Aarti Surfactants Limited (AARTISURF) | $2.18 Billion | 9.78% | 0.94x | $15.25 Million |
| ABM International Limited (ABMINTLLTD) | $214.51 Million | 3.09% | 0.89x | $300.21K |
| ACUTAAS CHEMICALS LTD (ACUTAAS) | $5.94 Billion | 14.02% | 0.29x | $226.24K |
| Advanced Enzyme Technologies Limited (ADVENZYMES) | $984.09 Million | 34.30% | 2.55x | $98.47 Million |
| Agarwal Industrial Corporation Limited (AGARIND) | $739.40 Million | 9.29% | 0.98x | $27.69 Million |
| Alkali Metals Limited (ALKALI) | $513.80 Million | 2.54% | 0.73x | $2.00 Million |
| Alkyl Amines Chemicals Limited (ALKYLAMINE) | $3.79 Billion | 22.71% | 1.01x | $208.93 Million |
| Ami Organics Limited (AMIORG) | $107.73 Million | 26.58% | 2.59x | $704.27 Million |
| Anupam Rasayan India Limited (ANURAS) | $2.50 Billion | 13.94% | 1.53x | $318.88 Million |